Citation: | YOU Meigui, CHEN Tong, NI Yuanning, JI hui. Effect of compound ursodeoxycholic acid oral liquid on cholestatic hepatitis in rats[J]. Journal of China Pharmaceutical University, 2014, 45(1): 102-105. DOI: 10.11665/j.issn.1000-5048.20140119 |
[1] |
Yu F,Liang FL,Deng MH,et al.Integrated therapy of traditional Chinese and western medicine in treating intrahepatic cholestasis[J].Mod J Integr Tradit Chin Western Med(现代中西医结合杂志),2013,22(9):1 019-1 021.
|
[2] |
Kondrackiene J,Beuers U,Kupcinskas L.Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy[J].Gastroenterology,2005,129(3):894-901.
|
[3] |
Chen QH.Role of methionine and Vitamin B1 for injection in the treatment of ICP[J].Mod Med Health(现代医药卫生),2011,27(12):1 841-1 842.
|
[4] |
Zhao L.Pharmacological exploration of corilagin on cholestatic hepatitis via anit-inflammation pathway(Corilagin对淤胆型肝炎炎症通路干预机制的初步研究)[D].Wuhan:Huazhong University of Science & Technology,2008.
|
[5] |
Cheng CL,Peng CX,Wei LS,et al.Effects of vitamin E or in combination with vitamin C or vitamin B2 on functions of the antioxidant system in mice[J].J Wuhan Univ Sci Technol(武汉科技大学学报),2000,23(3):313-315.
|
[6] |
Wang SH,Mei J,Chen QX,et al.Regulation of lipid peroxidation contributes to the liver protective effect of β-carotene and riboflavin in rats with intrahepatic cholestasis[J].Acta Nutr Sin(营养学报),1999,21(1):22-26.
|
[7] |
Xu XW,Li LJ,Lu FF,et al.Ursodeoxycholic acid therapy in rats with intrahepatic cholestasis[J].Chin J Hepatol(中国肝脏病杂志),2003,11(3):244-245.
|
[8] |
Yoshiji O,Mutsumi K,Emi S,et al.Change in hepatic antioxidant defense system with liver injury development in rats with a single alpha-naphthylisothiocyanate intoxication[J].Toxicology,1999,139(3):153-165.
|
[9] |
Sopjani M,Alesutan I,Wilmes J,et al.Stimulation of Na+-K+-ATPase activity and Na+ coupled glucose transport by β-catenin[J].Biochem Biophys Res Commun,2010,402(3):467-470.
|
[1] | YAO Lei, QU Linlin, FAN Daidi. Effects of rare ginsenoside on idiopathic pulmonary fibrosis[J]. Journal of China Pharmaceutical University, 2023, 54(5): 607-613. DOI: 10.11665/j.issn.1000-5048.2023042002 |
[2] | QIAN Xiuhui, SUN Jing, FU San, TANG Xiaoyan, XU Xianghong, ZHANG Mian. Effect of intratracheal instillation of PM2.5 suspensionon pulmonary fibrosis in mice and the intervention of neotuberostemonine[J]. Journal of China Pharmaceutical University, 2021, 52(4): 455-462. DOI: 10.11665/j.issn.1000-5048.20210408 |
[3] | LI Xiaoshi, WU Xunxun, ZHENG Zuguo, YANG Hua, LI Ping. Advances of long noncoding RNAs in myocardial fibrosis[J]. Journal of China Pharmaceutical University, 2020, 51(6): 646-654. DOI: 10.11665/j.issn.1000-5048.20200602 |
[4] | CAI Yanfei, WAN Aini, CHEN Yun, JIN Jian. Anti-liver fibrosis activities of the extracellular domain of transforming growth factor beta type II receptor fusion protein in vivo[J]. Journal of China Pharmaceutical University, 2019, 50(2): 246-252. DOI: 10.11665/j.issn.1000-5048.20190217 |
[5] | XIE Weina, DING Qi, SUN Jing, ZHANG Chaofeng, ZHANG Mian, XU Xianghong. Protective effects of Baibu Tang on bleomycin-induced pulmonary fibrosis in mice[J]. Journal of China Pharmaceutical University, 2018, 49(4): 483-489. DOI: 10.11665/j.issn.1000-5048.20180415 |
[6] | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[7] | ZHAO Limeng, WANG Shuzhen. Therapeutic applications of small molecule kinase inhibitors in liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(2): 147-157. DOI: 10.11665/j.issn.1000-5048.20180203 |
[8] | XIANG Juan, YU Ping, LI Mingdan, ZHANG Chaofeng, XU Xianghong, ZHANG Mian. Protective effects of stemona alkaloids on mice with bleomycin-induced pulmonary fibrosis[J]. Journal of China Pharmaceutical University, 2017, 48(1): 76-81. DOI: 10.11665/j.issn.1000-5048.20170112 |
[9] | DAI Li, ZHANG Lu, JI Hui, KONG Xiang-wen. Therapeutic effects of ZK14,a novel nitric oxide donating biphenyldicarboxylate derivative,on hepatic fibrosis in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 254-257. |
[10] | Danshen Inhibiting Isoproterenol Induced Cardiac Hypertrophy and Fibrosis in Mice and its Mechanisms[J]. Journal of China Pharmaceutical University, 2003, (6): 84-87. |